Table 1 Overlapped metabolites identified for the four different GWAS datasets of anxiety disorders
Description | Anxiety disorders diagnosed by psychiatrists | Unspecified anxiety disorders diagnosed by secondary ICD-10 | Anxiety disorders diagnosed by general practitioners | Self-reported anxiety | ||||
|---|---|---|---|---|---|---|---|---|
OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |
1-arachidonoylglycerophosphocholine | 0.975(0.958–0.992) | 0.004** | 0.993(0.987–0.999) | 0.020 | ||||
1-eicosatrienoylglycerophosphocholine | 1.017(1.001–0.033) | 0.039* | 1.045(1.022–1.069) | 0.000*** | ||||
1-linoleoylglycerophosphoethanolamine | 1.040(1.021–1.060) | 0.000*** | 1.054(1.025–1.084) | 0.000*** | ||||
adrenate (224n6) | 0.969(0.942–0.997) | 0.032* | 0.958(0.920–0.997) | 0.035* | ||||
androsterone sulfate | 1.010(1.003–1.016) | 0.007** | 1.009(1.001–1.017) | 0.031* | ||||
cholate | 1.009(1.002–1.017) | 0.011* | 1.004(1.001–1.007) | 0.005 | ||||
docosahexaenoate (DHA; 226n3) | 0.971(0.947–0.995) | 0.019* | 0.949(0.906–0.994) | 0.025* | ||||
epiandrosterone sulfate | 1.012(1.001–1.023) | 0.029* | 0.995(0.992–0.998) | 0.003 | ||||
gamma-glutamylphenylalanine | 0.961(0.935–0.987) | 0.003** | 0.959(0.921–0.999) | 0.043* | ||||
phenyllactate (PLA) | 0.958(0.933–0.984) | 0.002** | 0.952(0.907–0.998) | 0.041* | ||||
tryptophan betaine | 1.008(1.002–1.015) | 0.010* | 1.014(1.003–1.025) | 0.012* | ||||